Quantcast

Latest Talizumab Stories

2014-05-15 08:32:10

Rapid IgE clearance by XmAb7195 shows potential as a disease modifying treatment for allergy and asthma MONROVIA, Calif., May 15, 2014 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer, today announced it will present preclinical data comparing activity of XmAb®7195 to omalizumab in reducing IgE, a protein responsible...

2014-02-24 23:03:30

Houston Allergy & Asthma Associates reports new findings from research on more efficient and effective methods to treat asthma. Houston, TX (PRWEB) February 24, 2014 Houston Allergy & Asthma Associates reports new findings from research on more efficient and effective methods to treat asthma. The research, funded by Novartis Pharmaceuticals, appeared in Current Medical Research and Opinion this month. It concerns a novel liquid formulation of the monoclonal antibody omalizumab...

2011-03-28 08:18:48

(Ivanhoe Newswire) -- A drug that targets the antibody immunoglobulin E (IgE), a key player in asthma, nearly eliminated seasonal increases in asthma attacks and decreased asthma symptoms among young people living in inner city environments, a clinical trial sponsored by the National Institutes of Health has found. This investigational use of the drug omalizumab, sold under the brand name Xolair, was conducted in eight U.S. cities by the Inner City Asthma Consortium (ICAC), a nationwide...

2009-07-16 14:29:30

The U.S. Food and Drug Administration says it is conducting a safety review of Xolair, a drug used to treat moderate-to-severe persistent asthma. The FDA said reviewers are looking for a possible association between patients who use Xolair (omalizumab) and an increased risk of heart attack, abnormal heart rhythm, heart failure and stroke. A possible association was suggested by interim results from an ongoing study of the drug being conducted by the manufacturer, Genentech Inc. of San...

2008-10-06 09:00:09

Novartis has announced positive results from a Phase III clinical study, which showed that Xolair, a treatment for allergic asthma in adolescents and adults, significantly reduced asthma attacks in children aged six to 11 years with uncontrolled moderate-to-severe persistent allergic asthma. The study showed that after 24 weeks, children treated with Xolair suffered 31% fewer clinically significant exacerbations than those receiving placebo or dummy drug (p=0.007). The study therefore met...

2006-08-29 12:00:30

By Amy Norton NEW YORK (Reuters Health) - Children with peanut allergies may be less likely to accidentally eat peanut-containing foods than in years past, but the problem still needs attention, a Canadian study suggests. In a study of 252 children with peanut allergy, researchers found that over a year, about 14 percent accidentally ingested peanut allergens. That's lower than what's been reported in previous studies -- suggesting, according to the study authors, that preventive...

2006-01-13 12:18:03

NEW YORK (Reuters Health) - Individuals with severe persistent dermatitis who fail to gain adequate control despite standard treatments may find relief with the addition of Xolair (omalizumab), according to a group of dermatologists from Georgia. Xolair is a laboratory-generated monoclonal antibody that is given by injection. It is designed to bind to IgE, a naturally occurring antibody, and prevent it from triggering the release of chemicals that provoke asthma and allergy...


Word of the Day
call-note
  • The call or cry of a bird or other animal to its mate or its young.
'Call-note' is newer than 'bird-call,' which originally referred to 'an instrument for imitating the note of birds' but now also refers to 'the song or cry of a bird.'
Related